Jul 10 |
Enveric Biosciences Announces Patent Granted for Drug Candidate
|
Jul 8 |
Enveric Biosciences files $200M mixed securities shelf
|
Jul 1 |
Is Enveric Biosciences, Inc. (NASDAQ:ENVB) Trading At A 36% Discount?
|
Jun 25 |
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
|
May 30 |
Enveric Biosciences to Participate in BIO International Convention 2024
|
May 16 |
'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand
|
May 15 |
Enveric Biosciences GAAP EPS of -$0.61
|
May 15 |
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
|
May 14 |
Enveric Biosciences signs $66.5M non-binding term sheet with MindBio Therapeutics
|
May 14 |
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
|